Neuroscience and Behavioral Physiology

, Volume 40, Issue 5, pp 529–532

Use of the Glutamate NMDA Receptor Antagonist PK-Merz in Acute Stroke

  • O. V. Krivonos
  • N. A. Amosova
  • I. G. Smolentseva

Key words

stroke PK-Merz 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    E. I. Gusev and V. I. Skvortsova, “Current concepts in the treatment of acute cerebral stroke,” Consilium Medium, 2, No. 2, 60–65 (2000).Google Scholar
  2. 2.
    E. I. Gusev and V. I. Skvortsova, Cerebral Ischemia [in Russian], Meditsina, Moscow (2001).Google Scholar
  3. 3.
    E. I. Gusev, V. I. Skvortsova, and I. A. Platonova, “The treatment of ischemic stroke,” Consilium Medium, 18, 18–25 (special issue) (2003).Google Scholar
  4. 4.
    E. I. Gusev and P. R. Kamchatnov, “Nervous system plasticity,” Zh. Nevrol. Psikhiatr., 3, 73–79 (2004).Google Scholar
  5. 5.
    Stroke. Principles of Diagnosis, Treatment, and Prophylaxis: Brief Guidelines for Physicians [in Russian], N. V. Vereshchagin, M. A. Piradov, and Z. A. Suslina (eds.), Moscow (2002).Google Scholar
  6. 6.
    V. I. Skvortsov, “Mechanisms of the damaging influence of cerebral ischemia and new therapeutic strategies,” Zh. Nevrol. Psikhiat., 9, 20–25 (2003).Google Scholar
  7. 7.
    Z. A. Suslina, “Treatment of ischemic stroke,” Lech. Nervn. Bolez., 1, No. 1, 3–7 (2000).Google Scholar
  8. 8.
    Z. A. Suslina, T. N. Fedorova, N. Yu. Maksimova, et al., “Antioxidant treatment in ischemic stroke,” Zh. Nevrol. Psikhiat., 10, 34–39 (2000).Google Scholar
  9. 9.
    H. P. Adams, G. del Zoppo, M. J. Alberts, et al., “Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists,” Stroke, 38, 1655–1711 (2007).CrossRefPubMedGoogle Scholar
  10. 10.
    T. A. Blanpied, R. J. Clarke, and J. W. Johnson, “Amantadine inhibits NMDA receptors by accelerating channel closure during channel block,” J. Neurosci., 25, 3312–3322 (2005).CrossRefPubMedGoogle Scholar
  11. 11.
    J. J. Caro, K. F. Huybrechts, and H. E. Kelley, “Predicting treatment costs after acute ischemic stroke on the basis of patient characteristics at presentation and early dysfunction,” Stroke, 32, 100–106 (2001).PubMedGoogle Scholar
  12. 12.
    A. Cavallini, G. Micieli, S. Marcheselli, and S. Quaglini, “Role of monitoring in management of acute ischemic stroke patients,” Stroke, 34, 2599–2603 (2003).CrossRefPubMedGoogle Scholar
  13. 13.
    C. Culmsee, V. Junker, W. Kremers, et al., “Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol,” Stroke, 35, 1197–1202 (2004).CrossRefPubMedGoogle Scholar
  14. 14.
    S. M. Davis, K. R. Lees, G. W. Albers, et al., “Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist,” Stroke, 31, 347–354 (2000).PubMedGoogle Scholar
  15. 15.
    A. G. Dyker and K. R. Lees, “Duration of neuroprotective treatment for ischemic stroke,” Stroke, 29, 535–542 (1998).PubMedGoogle Scholar
  16. 16.
    A. Evans, F. Harraf, N. Donaldson, and K. Lalit, “Randomized controlled study of stroke unit care versus stroke team care in different stroke subtypes,” Stroke, 33, 449–455 (2002).CrossRefPubMedGoogle Scholar
  17. 17.
    M. Fisher, A. Dávalos, A. Rogalewski, et al., “Toward a multimodal neuroprotective treatment of stroke,” Stroke, 37, 1129–1136 (2006).CrossRefGoogle Scholar
  18. 18.
    L. A. Gillum and S. C. Johnston, “Characteristics of academic medical centers and ischemic stroke outcomes,” Stroke, 32, 2137–2142 (2001).CrossRefPubMedGoogle Scholar
  19. 19.
    K. W. Muir, “Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design,” Stroke, 33, 1454–1550 (2002).CrossRefGoogle Scholar
  20. 20.
    K. R. Lees, A. G. Dyker, A. Sharma, et al., “Tolerability of the lowaffinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients: a dose-ranging study,” Stroke, 32, 466–472 (2001).PubMedGoogle Scholar
  21. 21.
    K. R. Lees, J. A. Zivin, T. Ashwood, et al., “NXY-059 for acute ischemic stroke,” N. Eng. J. Med., 354, 588–600 (2006).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2010

Authors and Affiliations

  • O. V. Krivonos
    • 1
  • N. A. Amosova
    • 2
  • I. G. Smolentseva
    • 2
  1. 1.Department of the Organization of Medical Care and Healthcare DevelopmentMinistry of Health and Social Development of the Russian FederationMoscowRussia
  2. 2.A. I. Burnazyan Federal Medical Biophysics CenterFederal Medical Biological AgencyMoscowRussia

Personalised recommendations